Consolidated Statements of Cash Flows Statement (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net income including noncontrolling interests in operating subsidiaries	$ 56,034	$ 15,395
Adjustments to reconcile net income including noncontrolling interests in operating subsidiaries to net cash provided by operating activities:
Depreciation and amortization	10,585	6,418
Non-cash stock compensation	11,090	6,323
Change in valuation allowance	(10,237)	0
Other	49	(9)
Changes in assets and liabilities:
Accounts receivable	(7,907)	(12,379)
Prepaid expenses and other assets	(271)	(63)
Accounts payable and accrued expenses / costs	2,945	(497)
Royalties and contingent legal fees payable	(4,405)	9,931
Deferred income tax	(5,522)	0
Net cash provided by operating activities	63,405	25,119
Cash flows from investing activities:
Purchases of property and equipment	(188)	(88)
Purchase of available-for-sale investments	(239,952)	0
Maturities and sale of available-for-sale investments	117,462	35
Purchase of ADAPTIX, Inc., net of cash acquired	(150,000)	0
Patent acquisition costs	(40,435)	(1,805)
Net cash used in investing activities	(313,113)	(1,858)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	218,983	175,232
Distributions to noncontrolling interests in operating subsidiary	0	(2,897)
Contributions from noncontrolling interests in operating subsidiary	1,920	877
Excess tax benefits from stock-based compensation	10,850	23
Proceeds from exercises of stock options	88	404
Net cash provided by financing activities	231,841	173,639
(Decrease) increase in cash and cash equivalents	(17,867)	196,900
Cash and cash equivalents, beginning	314,733	102,515
Cash and cash equivalents, ending	296,866	299,415
Supplemental schedule of noncash investing activities:
Patent acquisition costs included in accrued expenses / costs	$ 10,000	$ 0